Transthyretin Amyloidosis (ATTR) Market Growth, Size, Share, Trends, Statistics Analysis Report By Type, By Application, By Region, and Forecasts 2022-2032


The Transthyretin Amyloidosis (ATTR) market is undergoing significant transformations as awareness about this rare and debilitating disease increases, and research efforts intensify. ATTR is a group of rare genetic disorders characterized by the abnormal accumulation of misfolded transthyretin protein, leading to the formation of amyloid deposits in various organs. The market for ATTR treatment has gained prominence due to a growing understanding of the disease's pathophysiology and an increasing number of diagnosed cases. With ATTR having both hereditary and sporadic forms, the market encompasses a broad spectrum of patients, presenting opportunities for pharmaceutical companies to address the diverse needs of this patient population.

**For Further Information Regarding this Report: Request a Free Sample**	

<https://thedatahorizzon.com/download-sample/?rid=542541>

In recent years, the ATTR market has seen a surge in research and development activities aimed at discovering effective therapies. Several pharmaceutical companies are actively engaged in developing novel drugs that target the underlying mechanisms of transthyretin amyloidosis. The advent of gene therapies and RNA-based therapeutics has opened new avenues for treatment, offering potential breakthroughs in managing the progression of the disease. The market's landscape is characterized by a mix of established pharmaceutical players and emerging biotechnology companies, each striving to bring innovative and effective treatments to market.

Despite advancements in research and drug development, challenges persist in the ATTR market. Limited awareness among healthcare professionals and the general population, coupled with the difficulty of early diagnosis, often leads to delayed treatment initiation. Additionally, the high cost associated with developing and manufacturing specialized therapies for rare diseases poses economic challenges for both patients and healthcare systems. Efforts to streamline diagnostic processes, enhance awareness campaigns, and collaborate on novel reimbursement models are crucial components in addressing these challenges and ensuring wider accessibility to ATTR treatments.

The ATTR market is witnessing a paradigm shift as stakeholders recognize the need for a holistic approach that combines scientific innovation with patient-centric solutions. Collaborations between pharmaceutical companies, research institutions, and patient advocacy groups are becoming more prevalent, fostering a supportive ecosystem for accelerating drug development and improving patient outcomes. As the ATTR landscape continues to evolve, there is optimism that ongoing research efforts and therapeutic advancements will pave the way for more effective treatments, ultimately improving the quality of life for individuals affected by this rare and complex disorder.

**For Further Information Regarding this Report: Ask for Discount**	

<https://thedatahorizzon.com/ask-for-discount/?rid=542541>

**Segments Covered in the Transthyretin Amyloidosis (ATTR) Market Report:**

This report forecasts revenue growth at global, regional, and country levels and offers an analysis of latest industry developments in each of the sub-segments from 2018 to 2032.

**Global Transthyretin Amyloidosis (ATTR) Market, By Type**

- Hereditary ATTR (HATTR)
- Wild-Type (WT) ATTR

**Global Transthyretin Amyloidosis (ATTR) Market, By Application**

- Hospitals
- Ambulatory Surgical Centers
- Diagnostic Centers

**Top 5 Key Players Transthyretin Amyloidosis (ATTR) Market:**

Akcea Therapeutics/Ionis Pharmaceuticals:

Akcea Therapeutics and Ionis Pharmaceuticals collaborated to develop and commercialize Tegsedi (inotersen), an RNA-targeted therapeutic for polyneuropathy caused by hereditary ATTR (hATTR) amyloidosis. The drug has been an important addition to the treatment options for ATTR patients.

Alnylam Pharmaceuticals:

Alnylam has been a significant player in the ATTR market with its product, Onpattro (patisiran). Onpattro is an RNA interference (RNAi) therapeutic for the treatment of the polyneuropathy of hATTR amyloidosis in adults. The drug received FDA approval and has contributed to advancements in ATTR treatment.

Pfizer Inc. (Vyndaqel/Vyndamax):

Pfizer has a presence in the ATTR market with Vyndaqel (tafamidis) and Vyndamax (tafamidis meglumine). These drugs are indicated for the treatment of cardiomyopathy caused by hATTR amyloidosis in adults. Vyndaqel was the first FDA-approved treatment for this indication, and Vyndamax offers an alternative formulation.

Eidos Therapeutics (Acquired by BridgeBio Pharma):

Eidos Therapeutics, which was later acquired by BridgeBio Pharma, focused on developing small molecule drugs for the treatment of ATTR amyloidosis. Their lead candidate, AG10 (now part of BridgeBio's pipeline), is an investigational therapy for both cardiomyopathy and polyneuropathy manifestations of hATTR amyloidosis.

Alnylam Pharmaceuticals/Sanofi:

Alnylam and Sanofi collaborated on the development and commercialization of patisiran (Onpattro) for the treatment of hATTR amyloidosis. This partnership has played a crucial role in bringing innovative RNAi-based therapies to the market.

**Want to change the report scope? Need Customization?**

<https://thedatahorizzon.com/need-customization/?rid=542541>

**Transthyretin Amyloidosis (ATTR) Market: Regional Insights**

North America

- U.S.
- Canada

` `Europe

- UK
- Germany
- France
- Rest of Europe

Asia Pacific	

- China
- Japan
- South Korea
- India
- Rest of Asia Pacific

Latin America

- Brazil
- Mexico
- Rest of Latin America

Middle East & Africa

- UAE
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa

**Read More:** <https://thedatahorizzon.com/product/transthyretin-amyloidosis-attr/>

**About DataHorizzon Research:**

DataHorizzon is a market research and advisory company that assists organizations across the globe in formulating growth strategies for changing business dynamics. Its offerings include consulting services across enterprises and business insights to make actionable decisions. DHR’s comprehensive research methodology for predicting long-term and sustainable trends in the market facilitates complex decisions for organizations.

**Contact:**

**Mail: <sales@datahorizzonresearch.com>**

**Ph:** **+1–970–672–0390**

**Website:** <https://thedatahorizzon.com/>

